Key Highlights

• BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB)
• BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB)
• MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance results in improvement in cognitive decline. (MRK, BIIB)
• There are many permutations of targets for AD, but there is no data that supports one being more efficacious than the other (amyloid antibodies, BACE inhibitors, tau antibodies).
• Current AD symptomatic treatments in Phase III development are “moon shots,” but they have supportive Phase II data.